Hypothesis

mTOR activity sets a bidirectional rheostat that determines whether exosomes carry cargo promoting cellular specialization and growth or cargo enforcing a stress‑resistant, minimally communicative state. When mTORC1 is high, exosomes are depleted of growth‑factor receptors and enriched in lysosomal degradation signals, limiting paracrine instruction. When mTORC1 is low, exosomes are loaded with specific miRNAs and anti‑oxidant enzymes that reprogram recipient cells toward autophagy and resistance, effectively broadcasting a ‘survival mode’ signal across tissues.

Mechanistic Model

• Cargo sorting switch: mTORC1 phosphorylates the ESCRT‑associated protein HRS, reducing its affinity for ubiquitinated growth‑factor receptors and increasing its binding to LC3‑associated sequences. This shifts exosome loading from receptor‑rich to LC3‑II‑rich cargo 1.
• Rab27A coupling: mTORC1 inhibition activates Rab27A via dephosphorylation by PP2A, promoting MVB docking to the plasma membrane and exosome release. Conversely, active mTORC1 sustains Rab27A phosphorylation, retaining MVBs for lysosomal fusion 2.
• Feedback loop: Exosomes released under low mTORC1 deliver miR‑30a and peroxiredoxin‑2 to recipient cells, where they suppress mTORC1 signaling by targeting RHEB and reducing ROS‑mediated AKT activation, reinforcing the low‑mTOR state in a paracrine fashion 3.
• Senostatic shift: In senescent cells, persistent mTORC1 blocks the autophagic loading route, causing exosomes to accumulate SASP factors (IL‑6, MMPs) that propagate inflammation. Pharmacological mTOR inhibition restores LC3‑II loading, converting the exosome profile from pro‑inflammatory to tissue‑repair 4.

Predictions and Experimental Tests

1. Phosphoproteomics: Inhibiting mTORC1 with rapamycin should decrease HRS phosphorylation (Ser‑XXX) and increase its association with LC3II. Measure by immunoprecipitation followed by mass spec; expectation: altered binding ratio correlates with exosome cargo shift.
2. miRNA enrichment: Exosomes harvested from mTORC1‑low cells will show ≥2‑fold increase in miR‑30a and peroxiredoxin‑2 mRNA compared with controls. Validate via qPCR on isolated exosomes; anticipate reversal upon mTORC1 reactivation with MHY1485.
3. Paracrine mTOR suppression: Treating naïve fibroblasts with exosomes from mTORC1‑low macrophages will reduce p‑S6K levels by ~40% within 6 h, an effect blocked by GW4869 (exosome release inhibitor) or anti‑miR‑30a oligonucleotides.
4. In vivo trade‑off: Mice treated with chronic low‑dose rapamycin will exhibit elevated circulating exosomes bearing LC3II and miR‑30a, accompanied by improved stress tolerance (e.g., reduced ischemia‑reperfusion injury) but decreased hypertrophic response to pressure overload. Opposite phenotype expected with mTORC1 hyperactivation via Rheb overexpression.
5. Falsification: If exosome cargo composition remains unchanged despite robust mTORC1 modulation, or if exosome transfer fails to alter recipient mTOR activity, the hypothesis is refuted.

Implications

This model reframes mTOR not merely as a cell‑autonomous growth switch but as a regulator of intercellular communication that toggles tissue‑scale programs between constructive specialization and protective dormancy. Therapeutically, targeting the mTOR‑exosome axis could fine‑tune the balance between regenerative growth and stress resistance without the need to eliminate senescent cells, offering a senomorphic strategy applicable to neurodegeneration, vascular calcification, and frailty.